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Summary: Dmp1 (cyclin D-interacting myb-like protein 1; also called Dmtf1) is a transcription factor that has been isolated 
in a yeast two-hybrid screen through its binding property to cyclin D2. Dmp1 directly binds to and activates the Arf promoter 
and induces Arf-p53-dependent cell cycle arrest in primary cells. D-type cyclins usually inhibit Dmp1-mediated transcrip-
tion in a Cdk-independent fashion; however, Dmp1 shows synergistic effects with D-cyclins on the Arf promoter. Ras or 
Myc oncogene-induced tumor formation is accelerated in both Dmp1
+/− and Dmp1
−/− mice with no signiﬁ  cant differences 
between Dmp1
+/− and Dmp1
−/−. Thus, Dmp1 is haplo-insufﬁ  cient for tumor suppression. Tumors from Dmp1
−/− or Dmp1
+/− 
mice often retain wild-type Arf and p53, suggesting that Dmp1 is a physiological regulator of the Arf-p53 pathway. The 
Dmp1 promoter is activated by oncogenic Ras-Raf signaling, while it is repressed by physiological mitogenic stimuli, 
overexpression of E2F proteins, and genotoxic stimuli mediated by NF-κB. The human DMP1 gene (hDMP1) is located 
on chromosome 7q21 and is hemizygously deleted in approximately 40% of human lung cancers, especially those that retain 
normal INK4a/ARF and P53 loci. Thus, hDMP1 is clearly involved in human carcinogenesis, and tumors with hDMP1 
deletion may constitute a discrete disease entity.
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Introduction
D-type cyclins (D1, D2, and D3) are induced in the context of a delayed early response to growth factor 
stimulation. Cyclin-dependent kinases 4 and 6 (Cdk4 and Cdk6) are synthesized and assemble with 
D-type cyclins’ catalytic partners, and both of these processes depend on the presence of mitogens 
(Giacinti and Giordano, 2006; Sherr, 1996, 2000; Sherr and Robers, 2004). Cyclin D-Cdk holoenzymes 
have two distinct functions in promoting progression through the G1 phase of the cell division cycle: 
1) catalysis of the phosphorylation of the retinoblastoma protein (pRb), and 2) accumulation of cyclin 
D-Cdk holoenzymes that recruit Cdk inhibitors (such as p27
Kip1 and p21
Cip1) into higher order complexes, 
thereby neutralizing their effects on other Cdks. This process facilitates the activation of cyclin E-Cdk2 
later in the G1 phase (Giacinti and Giordano, 2006; Sherr, 1996, 2000; Sherr and Robers, 2004). Among 
three D-type cyclins, the Cyclin D1 gene is most commonly involved in human cancers. The human 
Cyclin D1 gene is located on chromosome 11q13 and is often ampliﬁ  ed (∼15%) and overexpressed 
(∼50%) in breast cancers (Arnold and Papanikolau, 2006; Roy and Thompson, 2006). Cyclin D1 ampli-
ﬁ  cation is also found in head and neck, esophageal, and hepatocellular carcinomas and is associated 
with poor prognosis for patients (for reviews, Donnellan and Chetty, 1997; Sherr, 1996).
The human chromosome 9p21 locus has three different genes that have tumor suppressor functions, 
namely cyclin-dependent kinase inhibitor 2A (CDKN2A): p16
INK4a and p14
ARF (INK4a/ARF) and 
CDKN2B: p15
INK4b, respectively (Sherr, 2004). The former INK4a/ARF locus is one of the most fre-
quently disrupted genetic loci in human cancer, the frequency of which is second only to P53 mutations 
(Ruas and Peters, 1998). The activity of p53 is positively regulated by p19
Arf (p14
ARF in humans) in 
response to oncogenic stress (Lowe and Sherr, 2003; Sherr, 2001, 2006). p19
Arf directly binds to Mdm2, 
thereby stabilizing and activating p53, whereas p16
Ink4a binds to cdk4 to inhibit Rb phosphorylation 
(for reviews, Kim and Sharpless, 2006; Lowe and Sherr, 2003; Sherr, 2001, 2004, 2006). Arf is induced 
by potentially harmful growth-promoting signals stemming from overexpression of various oncoproteins 
(Lowe and Sherr, 2003; Sherr, 2001). This Arf induction forces early-stage cancer cells to undergo 210
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p53-dependent and -independent cell cycle arrest 
or apoptosis, providing a potent mode of tumor 
suppression. The Arf promoter monitors latent 
oncogenic signals in vivo (Zindy et al. 2003), and 
accordingly, Arf-null mice are highly prone to 
spontaneous tumor development, especially glio-
blastomas, carcinomas, and ﬁ  brosarcomas (Kamijo 
et al. 1999). Accumulating evidence has demon-
strated the p53-independent functions of Arf 
(reviewed in Sherr, 2006). The Arf promoter is 
positively regulated by the Dmp1 transcription 
factor, which will be explained in great detail in 
this review, and negatively regulated by Ink4a/Arf 
modulators such as Bmi1, Twist, Tbx2/3, and 
Pokemon (Inoue et al. 2007; Sherr, 2001).
Isolation of the Dmp1 Gene
In 1996, Hirai and Sherr reported the possibility 
that cyclin D/Cdks might regulate gene expres-
sion in an Rb-independent way, suggesting that 
D-cyclins may involve other genetic programs 
to facilitate progression of the cell cycle (Hirai 
and Sherr, 1996). They isolated a novel protein 
named Dmp1 (cyclin D binding myb-like protein 
1; also called Dmtf1, cyclin D binding myb-like 
transcription factor 1) by using a yeast two-hybrid 
interactive screen of a murine T-lymphocyte 
library, with cyclin D2 as bait. The myb gene 
family consists of three members, named A, B 
and c-myb which encode nuclear proteins. These 
proteins function as transcriptional activators or 
repressors of genes that are involved in cell pro-
liferation, differentiation, apoptosis, and other 
biological processes. Members of the myb gene 
family show different temporal and spatial 
expression patterns suggesting a distinctive func-
tion for each of these genes. Loss of the prototype 
c-myb function in mice results in embryonic 
lethality due to failure of fetal hepatic hemato-
poiesis (Oh and Reddy, 1999). Dmp1 binds 
speciﬁ  cally to the nonameric DNA consensus 
sequences CCCG(G/T)ATGT to activate tran-
scription (Hirai and Sherr, 1996). Although 
Dmp1 is related to the myb family proteins for 
this structure, a subset of these Dmp1 recognition 
sequences contains a GGA trinucleotide core, a 
responsive element shared by Ets proteins (Hirai 
and Sherr, 1996). Inoue and Sherr reported that 
Dmp1 has a central DNA binding domain that 
contains three imperfect Myb-like repeats 
between two acidic transactivation domains. 
(Fig. 1; Inoue and Sherr, 1998). One experiment 
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Figure 1. Structure and protein interacting surfaces of Dmp1 and cyclin D1.
Top. The structure of the Dmp1 transcription factor. Dmp1 consists of 761 amino acids in mice and 760 amino acids in humans, and undergoes 
extensive posttranslational modiﬁ  cation. It has a central DNA-binding domain with three Myb-like repeats that are essential for DNA binding. 
Mutation of lysine at 319 to glutamic acid abolishes its DNA binding. Bottom. Cyclin D1 binds to its catalytic partner Cdk4 through the cyclin 
box (orange box, amino acid residues 56 to 152). Mutation of lysine at 112 or 114 to glutamic acid abolishes its binding property to Cdks. 
Cyclin D1 binds to Dmp1 through its carboxyl-terminal half that overlaps the region for estrogen receptor interaction (Inoue and Sherr, 1998; 
Zwijsen et al. 1997). Cyclin D1 also interacts with TAFII250 (Adnane et al. 1999) and androgen receptors (Reutens et al. 2001). 
Abbreviations: ER: estrogen receptor; SRC: steroid receptor coactivator; TAFII250: TATA-binding protein-associated factor; AR: androgen 
receptor.211
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with recombinant Dmp1 proteins prepared in Sf9 
cells shows that Dmp1 does not need to form 
homodimers to bind to DNA, although Dmp1 can 
form homodimers in the absence of DNA (Inoue 
et al. unpublished data). Dmp1 does not have a 
clear nuclear localization signal although the 
protein is localized in the nucleus in transfected 
as well as in normal cells (Inoue and Sherr, 1998; 
Mallakin et al. 2006).
The Dmp1 protein migrates at 120–130 kDa 
although the expected molecular weight is 
∼ 85 kDa, suggesting the presence of signiﬁ  cant 
post-translational modiﬁ  cations (Hirai and Sherr, 
1996; Inoue and Sherr, 1998). D-type cyclins asso-
ciate with a region of the Dmp1 DNA-binding 
domain immediately amino-terminal to the tandem 
Myb-like repeats, to form heteromeric complexes 
that do not detectably interact with Cdk4 or DNA 
(Fig. 1; Inoue and Sherr, 1998). Interestingly, the 
segment of D-type cyclins required for its interac-
tion with Dmp1 was mapped outside the ‘cyclin 
box’, which contains the residues predicted to 
contact Cdk4 (Inoue and Sherr, 1998). It was 
reported that the estrogen receptor binds with 
cyclin D1 outside the cyclin box (Zwijsen et al. 
1997). They showed that cyclin D1 activates estro-
gen receptor-mediated transcription in the absence 
of estrogen and enhances transcription in its pres-
ence. Interestingly, Reutens et al. reported that the 
androgen receptor interacts with cyclin D1 through 
its carboxyl-terminal residues (Reutens et al. 
2001). These studies indicated the carboxyl-
terminal domain of cyclin D1 plays an important 
role in physical interactions with DNA-binding 
proteins, completely independent of cyclin D bind-
ing to Cdks (Bernards, 1999; Coqueret, 2002; 
Inoue et al. 2007). The physiological roles of Cdk-
independent functions of cyclin D1 in breast and 
retinal development has recently been reported 
(Landis et al. 2006).
Overexpression of the Dmp1 gene in mouse NIH 
3T3 ﬁ  broblasts inhibits their entry into S phase 
(Inoue and Sherr, 1998). Cell cycle arrest depended 
on the ability of Dmp1 to bind to DNA and transac-
tivate gene expression, and was speciﬁ  cally antago-
nized by coexpression of D-type cyclins, including 
cyclin D1 point mutants (D1K112E, K114E) that do 
not bind to Cdk4 (Inoue and Sherr, 1998; Fig. 1). 
Studies from other laboratories also showed that 
overexpression of D-type cyclins inhibited transcrip-
tional activities of other Myb proteins, v-Myb and 
B-Myb (Ganter et al. 1998; Horstmann, 2000), 
suggesting a functional link between D-cyclins and 
Myb-like proteins (Inoue et al. 2007).
Regulation of the Arf-Mdm2-p53 
Pathway by Dmp1
Through extensive search for Dmp1-consensus 
sequences on naturally occurring promoters, it was 
found that the murine and human Arf promoters 
and the human CD13/Aminopeptidase N have 
high-affinity Dmp1-binding sequences (Inoue 
et al. 1998, 1999). Dmp1 directly binds to a unique 
consensus site 5’-CCCGGATGC-3’ on the murine 
Arf promoter to activate its gene expression 
(Inoue et al. 1999). Dmp1-mediated Arf promoter 
activation depended on the consensus sequence. 
When inducible Dmp1:ER virus-infected MEFs 
(murine embryonic ﬁ  broblasts) were stimulated 
with 4-hydroxytamoxifen (4-HT), both Arf mRNA 
and protein were upregulated, which induced Arf-, 
p53-dependent cell cycle arrest within 48 hours 
(Inoue et al. 1999). E2F1 and Dmp1 showed addi-
tive effects on the Arf promoter. Since Dmp1 
overexpression does not induce apoptosis, it was 
concluded that p19
Arf can be induced in response 
to anti-proliferative stimuli that do not obligatorily 
lead to cell death (Inoue et al. 1999).
The mice that lack Dmp1 have been created by 
disrupting exons that encode the Myb-like repeats 
(Inoue et al. 2000). Dmp1-null mice are 20%–30% 
smaller than their wild-type counterparts at birth. 
Male Dmp1
−/− adult mice remained smaller than 
their wild-type littermates while female Dmp1-null 
adult mice became indistinguishable from their 
Dmp1
+/+ or Dmp1
+/− littermates. Dmp1-null mice 
have other miscellaneous phenotypes, such as 
generalized seizures, abnormal seminal vesicle 
dilatation in males, and poor mammary gland 
development in females (Inoue et al. 2000).
In cell culture, the growth of Dmp1-null MEFs is 
progressively retarded; however, p19
Arf and p53 
levels remain relatively low and the MEFs continued 
to grow slowly without reaching senescence (Inoue 
et al. 2000). On the other hand, the rate of p16
Ink4a 
induction in Dmp1-null cells remained largely iden-
tical to those in Dmp1
+/+ and Dmp1
+/− cells. Intrigu-
ingly, the levels of Dmp1 increased from passage 2 
to passage 3 in both Dmp1
+/+ and Dmp1
+/− cells, and 
the accumulation of Dmp1 preceded that of p19
Arf 
(Inoue et al. 2000). This data suggested that stress 
signaling caused by non-physiological cell culture 
conditions induces Dmp1, which in turn activates 212
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p19
Arf. When wild-type MEFs were continuously 
cultured over the period of replicative senescence, 
immortalized cell lines that had either a mutant 
p53 (∼80%) or deleted Arf locus (∼20%) were 
obtained (Inoue et al. 2000). In long term culture, 
Dmp1
−/− cells readily gave rise to established cell 
lines that retained wild-type Arf and functional p53 
without overexpression of Mdm2, suggesting that 
the activity of the Arf-Mdm2-p53 pathway is sig-
niﬁ  cantly attenuated in Dmp1
−/− cells (Inoue et al. 
2000). Hence Dmp1-deﬁ  cient MEFs were morpho-
logically transformed by Ha-Ras
V12 alone (Inoue 
et al. 2000).
Tumor Formation in Dmp1-
Deﬁ  cient Mice
The Dmp1-null mice developed tumors in their 
second year of life with a mean latency of 83 weeks 
(Inoue et al. 2001). These Dmp1-null mice spon-
taneously developed pulmonary adenomas/adeno-
carcinomas (42%), vascular tumors (hemangiomas 
and hemangiosarcomas) (24%), liver tumors 
(hepatocellular adenomas/adenocarcinomas) 
(18%) and B-cell lymphomas (15%) (Inoue et al. 
2001; Fig. 2). The time of tumor onset and the 
spectra of tumors observed in Dmp1-null mice bore 
no obvious relationship to those in Arf-null or p53-
null mice, which exhibit a different spectrum 
(Kamijo et al. 1999; Donehower et al. 1992). 
Treatment of neonatal Dmp1-deﬁ  cient mice with 
dimethylbenzanthracene (DMBA) or ionizing 
radiation helped to develop multiple tumors, 
including lung, skin, and liver carcinomas, T-cell 
leukemia/lymphomas, and ovarian tumors (Inoue 
et al. 2000, 2001; Fig. 2). The control Dmp1
+/+ mice 
that had received the same treatment were not 
found to have these tumors. These results suggest 
that Dmp1-inactivation clearly contributed to the 
change the tumor spectra. In humans, epithelial 
tumors such as adenocarcinomas are usual and 
carcinomas are commonly found after 40 years of 
age. Since Dmp1-null mice developed epithelial 
tumors in their second year of life, the Dmp1-
knockout mice may be useful carcinogenesis 
models for adult humans.
Haploid Insufﬁ  ciency of Dmp1 
in Tumor Suppression
When crossed onto a Dmp1
+/− or Dmp1
−/− back-
ground, lymphomas induced by the Eµ-Myc trans-
gene were greatly accelerated (mean latency, 12 
weeks) with no differences between cohorts lacking 
one or two Dmp1 alleles (Inoue et al. 2001). The 
latency in the Dmp1
+/− or Dmp1
−/− strains is similar 
to that of Arf 
+/−, Eµ-Myc transgenic mice (Eischen 
et al. 1999; Inoue et al. 2001). These results 
AB C
D EF
Figure 2. Tumors found in Dmp1-deﬁ  cient mice. 
A: mandibular carcinosarcoma (Dmp1
−/−, untreated, 76 weeks); B: T-cell leukemia/lymphoma (Dmp1
+/−, untreated, 48 weeks); C: lung 
adenocarcinoma (Dmp1
−/−, untreated, 86 weeks); D: ovarian granulose cell tumor (Dmp1
−/−, DMBA-treated, 26 weeks); E: hepatocellular 
carcinoma (Dmp1
+/−, irradiated, 61 weeks); and F: malignant melanoma (Dmp1
−/−, DMBA-treated, 39 weeks). These tumors were not 
observed in the Dmp1
+/+
 littermate controls of the same age (Inoue et al. 2000, 2001).213
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consistently suggest that Dmp1 loss lowers p19
Arf 
expression (Inoue et al. 1999, 2000). On the other 
hand, tumors from Dmp1-heterozygotes retained 
and expressed the wild-type Dmp1 allele and 
expressed detectable Dmp1 protein (Inoue et al. 
2001). In ﬁ  ve of these tumors, nucleotide sequenc-
ing by using reverse transcription-polymerase chain 
reaction products showed no mutations in the DNA-
binding domain in Dmp1. These results clearly 
conﬁ  rm that Dmp1 is haplo-insufﬁ  cient for tumor 
suppression (Inoue et al. 2001, 2007; for reviews, 
Brooksbank, 2001; Quon and Berns, 2001). Impor-
tantly, the combined frequencies of p53 mutation 
and Arf deletion in the Dmp1
−/− and Dmp1
+/− cohorts 
were ∼10%, versus ∼50% in Dmp1
+/+ littermates, 
suggesting that Dmp1 is a physiological regulator 
of the Arf-p53 pathway in living animals.
Activation of Dmp1 Transcription 
by Oncogenic Ras-Raf Signaling
Ras-mediated signaling pathways play critical roles 
in the mitogen-dependent induction of cyclin D1 
and its assembly with Cdk4 (Cheng et al. 1998). 
Overexpression of activated Ras stimulates DNA 
synthesis independent of growth factor stimulation. 
Conversely, continuous overexpression of onco-
genic Ras and its various effectors can lead to 
irreversible cell cycle arrest by upregulating the 
levels of p16
Ink4a, p19
Arf, and p53 (Lin et al. 1998; 
Palmero et al. 1998; Serrano et al. 1997; for review 
McMahon and Woods, 2001). It has been specu-
lated that transcriptional control plays an important 
role in Dmp1 regulation because the Dmp1 protein 
has a relatively long half-life (∼12 hours) (Mallakin 
et al. 2006). In cultured primary cells, the Dmp1 
promoter was efﬁ  ciently activated by oncogenic 
Ha-Ras
V12 but not by overexpressed c-Myc or 
E2F-1 (Sreeramaneni et al. 2005). Double mutant 
Ras
V12S35 activated the Dmp1 promoter, and MEK/
ERK inhibitor U0126 completely blocked the 
Dmp1 promoter activation, indicating that the 
Dmp1 promoter activation by Ras
V12 depended on 
Raf-MEK-ERK signaling (Sreeramaneni et al. 
2005). Consistently, Dmp1-null cells were resistant 
to Raf-mediated premature senescence, which 
showed signiﬁ  cantly decreased induction of p19
Arf 
and p21
Cip1 by oncogenic Raf (Sreeramaneni et al. 
2005). These results revealed that Dmp1 is a 
critical target for oncogenic Raf-induced premature 
senescence. Importantly, a Ras
V12-responsive ele-
ment was located onto the 50-base-pair leader 
sequence of the murine Dmp1 promoter, where 
endogenous Fos and Jun family proteins bind. The 
Dmp1 promoter activation by Ras
V12 was signiﬁ  -
cantly attenuated in c-Jun as well as in JunB knock-
down cells, suggesting Jun proteins have a critical 
role in Dmp1 promoter activation (Sreeramaneni 
et al. 2005). It is generally believed that c-Jun is 
phosphorylated by JNK/SAPK, the activity of 
which is regulated by the MEKK1-MEK4/7 path-
way. This MEKK1-MEK4/7-JNK/SAPK signaling 
is different from the classical Raf-MEK1/2-
ERK1/2 pathway (Johnson and Lapadat, 2002; 
Kallunki et al. 1996; Shaulian and Karin, 2002). 
However, it has also been reported that oncogenic 
Ras activates MEKK1 (Marshall, 1995). Thus, 
c-Jun phosphorylation is regulated by Ras signal-
ing. On the other hand, the c-Jun promoter is 
regulated by the Ras-Raf-MEK1/2-ERK1/2-MSK-
ATF1 pathway (Gupta and Prywes, 2002). For 
JunB, it has been reported that activated p44
ERK-1 
enhances Ets-mediated transactivation of the JunB 
promoter in response to Ras signaling, but JNKs 
do not phosphorylate JunB (Coffer et al. 1994; 
Kallunki et al. 1996). Thus, oncogenic Ras regu-
lates the Dmp1 promoter both by transcriptional 
activation of the c-Jun/JunB promoters and by 
phosphorylation of the c-Jun protein.
A Ras
V12-responsive element was mapped to 
the unique Dmp1/Ets site on the Arf promoter, 
where endogenous Dmp1 proteins bind after onco-
genic Raf activation (Sreeramaneni et al. 2005). 
Although oncogenic Ras indirectly activates E2F 
transcription factors, E2Fs do not play an important 
role in Arf induction by Ras
V12 (Palmero et al. 
2002; Rowland et al. 2002). Therefore, the Arf 
promoter activation induced by Ras/Raf signaling 
is mediated by Dmp1, and this is why Dmp1-null 
primary cells are highly susceptible to Ras-induced 
transformation (Inoue et al. 2000). We proposed 
that the novel Jun-Dmp1 pathways directly links 
oncogenic Ras-Raf signaling and p19
Arf, indepen-
dent of the classical cyclin D1/Cdk4-Rb-E2F 
pathway (Fig. 3; Sreeramaneni et al. 2005).
Overexpressed D-type cyclins usually antago-
nize Dmp1’s transcriptional activity in a Cdk-
independent fashion when tested with artiﬁ  cial 
promoter-reporter plasmids (containing con-
catamerized Dmp1 consensus binding sequences), 
or with some natural occurring promoters (such as 
those derived from the CD13/Aminopeptidase N 
gene) (Inoue et al. 1998). However, the results were 
reversed for the Arf promoter where D-type cyclins 214
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cooperated to enhance the activity of Dmp1 in a 
Cdk4-dependent manner. The Arf promoter has 
both Dmp1- and E2F-binding sites, enabling 
Ras
V12-induced cyclin D1 to assemble with Cdk4, 
promote to release E2Fs from pocket proteins, and 
then collaborate with Dmp1 in activating Arf gene 
expression (Inoue et al. 1999; Sreeramaneni et al. 
2005). On the other hand, the CD13/Aminopepti-
dase N promoter, which lacks E2F-consensus 
sequences, can be suppressed by D-type cyclins, 
which can interfere with Dmp1 binding to DNA 
when overexpressed. Interestingly, the Dmp1/Ets-
consensus sequences found within these two pro-
moters are completely identical (CCCGGATGC) 
(Inoue et al. 1998, 1999). Thus, the sequences 
flanking the Dmp1-binding site determine the 
responsiveness of the promoter to D-type 
cyclins.
Negative Regulation of the Dmp1 
Promoter: Repression by E2Fs 
and NF-κB
In wild-type MEFs, the Arf promoter is occupied 
by E2F3 and not other E2F family members. In 
quiescent cells, this role is largely fulﬁ  lled by 
E2F3b, an E2F3 isoform whose function was pre-
viously undetermined (Aslanian et al. 2004; for 
E2F review, Taneja et al. 2007; Trimarchi and Lees, 
2002). On the other hand, endogenous activating 
E2Fs, E2F1 and E2F3a are recruited to the Arf 
promoter in response to hyperproliferative onco-
genic signaling, indicating that distinct subsets of 
E2F proteins contribute to physiological repression 
and oncogenic activation of Arf (Aslanian et al. 
2004). The Dmp1 promoter was efficiently 
repressed by overexpression of E2F1, E2F2, E2F3a, 
Growth Arrest or 
Apoptosis
mitogenic 
signals
Ras
Cdk4 
Cyclin D1
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Myc
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Figure 3. Signaling pathways involving Dmp1. 
Arf is induced by potentially oncogenic signals stemming from overexpression of oncogenes such as c-Myc, E2F-1, and activated Ras. This 
induction quenches inappropriate mitogenic signaling by diverting incipient cancer cells to undergo p53-dependent and -independent growth 
arrest or cell death. Arf expression is repressed by a number of nuclear proteins, such as Bmi1, Twist, Tbx2/3, and Pokemon. Dmp1 is unique 
in that it directly binds and activates the Arf promoter and induces cell cycle arrest in an Arf-dependent fashion. Both Dmp1-null and hetero-
zygous mice show hypersensitivity to develop tumors in response to carcinogen DMBA and γ-irradiation. This phenotype could be explained 
by the inactivation of the Arf-Mdm2-p53 pathway in the absence of the functional Dmp1 protein, although it is possible that Dmp1 has targets 
other than Arf. D-type cyclins inhibit Dmp1’s transcriptional activity in a Cdk-independent fashion when E2Fs do not bind to the same pro-
moter; however, D-cyclins cooperate with Dmp1 to activate the Arf promoter. The Dmp1 promoter is efﬁ  ciently activated by the oncogenic 
Ras-Raf-MEK-ERK-Jun pathway but is repressed by overexpressed c-Myc, E2Fs, and by physiological mitogenic signaling. The induction 
of Arf by oncogenic Ras is largely dependent on Dmp1. We recently reported that the Dmp1-Arf pathway was inhibited by NF-κB proteins 
in response to genotoxic stress signaling (Taneja et al. 2007).215
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E2F3b, and E2F4 as well as physiological mitogens 
(Mallakin et al. 2006). Chromatin immunopre-
cipitation demonstrated the binding of endogenous 
E2Fs on the Dmp1 promoter when synchronized 
cells entered the S phase of the cell cycle (Mallakin 
et al. 2006). E2F-DB is a mutant of E2F1 that lacks 
a transactivation domain. Disruption of transcrip-
tional repressor complexes with E2F-DB causes a 
general increase of E2F target genes, but the cells 
become immortalized and are resistant to senes-
cence by p19
Arf, p53, and Ras
V12 (Rowland et al. 
2002). The Dmp1 mRNA was not downregulated 
in E2F-DB(+) cells in response to serum, suggest-
ing that the Dmp1 promoter repression by serum 
was E2F-dependent (Mallakin et al. 2006). Thus, 
E2F1 has differential effects on the Dmp1 promoter 
(repression) and the Arf promoter (activation) when 
overexpressed in rodent ﬁ  broblasts (Inoue et al. 
1999; Mallakin et al. 2006). The hDMP1 promoter 
also has a typical E2F site and is efficiently 
repressed by E2Fs (Mallakin et al. 2006). Although 
the mechanisms by which non-physiological E2F 
expression have differential effects on the Dmp1 
and Arf promoters are not clear, the simplest expla-
nation is that the differences of the ﬂ  anking DNA 
sequences around the E2F sites determine the 
responsiveness of each promoter to E2Fs since 
distinct cofactors will bind to each promoter. Of 
note, the Dmp1 promoter is not the only one that 
is repressed by ‘activating’ E2Fs; repression of the 
human telomerase promoter, tumor suppressor 
ARHI promoter, and PNRC2 (Proline-rich Nuclear 
Receptor Coactivator 2) promoter by E2F1 have 
been reported (Crowe et al. 2001; Lu et al. 2006; 
Zhou et al. 2005).
The Dmp1 is expressed in the testis, thymus, 
spleen, lung brain, and intestines (Inoue et al. 2000; 
Mallakin et al. 2006). In order to identify Dmp1-
expressing cells in vivo, immunohistochemical 
stainings were performed to disclose the Dmp1 
expression pattern in normal murine tissues com-
pared with the proliferation marker Ki67 (Mallakin 
et al. 2006). Ki67 antigen is the prototypic cell 
cycle-related nuclear protein, expressed by prolif-
erating cells in all phases of the active cell cycle 
(G1, S, G2 and M phase) (Brown and Gatter, 2002). 
It is absent in resting (G0) cells. Thus, Ki67 anti-
bodies are useful in establishing the cell growing 
fraction in neoplasms. The correlation between 
high Ki67 index and histologically high grade 
tumors is strong. High Ki67 index is associated 
with poor prognosis of a variety of human cancers 
(Brown and Gatter, 2002; Diest et al. 2004). In the 
thymus, nuclei of mature T lymphocytes in the 
medulla were strongly positive for Dmp1, whereas 
Ki67 was detected only in the cortex. In the intes-
tines, Dmp1 was detected in the nuclei of superﬁ  -
cial layers of the villi, whereas Ki67-positive cells 
were conﬁ  ned to the bottom of the crypt. Double 
staining for Dmp1 and Ki67 revealed that these 
two proteins were expressed in a mutually exclu-
sive fashion in nearly all of the tissues examined 
(Mallakin et al. 2006). The prototype of Dmp1, the 
c-Myb protein, is abundantly expressed in the 
thymic cortex (Oh and Reddy, 1999). Thus, c-Myb 
and Dmp1 may play complementary roles in regu-
lating the gene expression involved in cell growth 
and differentiation.
The Dmp1 and Arf promoters receive non-
oncogenic signals as well. Both genotoxic and 
oncogenic stress activates the nuclear factor-kappa B 
(NF-κB) and p53 proteins; however, p53 activity 
is antagonized by NF-κB signaling (Perkins, 
2004). Among NF-κB proteins, the p65, p50, and 
p52 subunits are ubiquitously expressed whereas 
the RelB and c-Rel subunits are relatively speciﬁ  c 
to lymphoid/hematopoietic tissues (Carrasco et al. 
1993; Hayden and Ghosh, 2004). The Dmp1 pro-
moter was repressed by treatment of cells with 
anthracyclins and UV-C; non-classical NF-κB 
activators (Taneja et al. 2007; Fig. 3). Following 
anthracyclin/UV-C treatment, p65 and other sub-
sets of NF-κB proteins were bound to the Dmp1 
promoter (Taneja et al. 2007). Repression of Dmp1 
transcription by anthracyclins depended on the 
unique NF-κB site on the promoter. Among 
NF-κB proteins, p65 played the major role in 
Dmp1 repression since downregulation of p65 by 
shRNA signiﬁ  cantly attenuated the response of 
the promoter by anthracyclins/UV-C. The amount 
of Dmp1 bound to the Arf promoter decreased 
signiﬁ  cantly upon anthracyclin treatment; this 
treatment, in turn, downregulated the p19
Arf. 
Repression of the Arf promoter by p65 or anthra-
cyclins depended on Dmp1, which was almost 
absent in Dmp1
−/− cells (Taneja et al. 2007). 
Compared to wild-type cells, both Dmp1
−/− and 
Arf 
−/− cells showed resistance to anthracyclin-
induced cell death. Non-immortalized p65-
knockdown cells were much more sensitive to 
anthracyclins than wild-type cells, indicating the 
role of p65 in protecting cells from apoptosis 
(Taneja et al. 2007). Thus, the Dmp1-Arf pathway 
is repressed by NF-κB in response to genotoxic 216
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stress, which implicates a novel mechanism of p53 
inactivation by NF-κB (Fig. 3).
What is the signiﬁ  cance, then, of inhibition of 
the Dmp1-Arf signaling by genotoxic stress? 
Doxorubicin treatment of cells stimulates nuclear 
accumulation and phosphorylation of p53, a process 
that is mediated by ATM (Kurz et al. 2004). Taneja 
et al. showed that Dmp1-Arf and p53 were differ-
entially regulated by anthracyclins for at least 4 hrs 
after drug treatment; however, both p53 and p21
Cip1 
decreased when Dmp1 and p19
Arf were downregu-
lated (Taneja et al. 2007). Thus, attenuation of the 
Dmp1-Arf pathway by anthracyclins appears to 
mediate protection of normal cells from the exten-
sive cell death induced by genotoxic drugs. This 
mechanism will be especially important with respect 
to the side effects of chemotherapeutic agents in 
normal tissues. The major mechanisms of action of 
anthracyclins are considered to be stabilization of 
topoisomerase IIα cleavage complexes and genera-
tion of reactive oxygen intermediates (DeVita et al. 
2005). The former causes protein-linked double- and 
single-stranded DNA breaks, which lead to cyto-
toxic DNA damage and cell death. Thus, cancer cells 
are generally much more sensitive to anthracyclins 
than normal tissues even when they have ARF dele-
tions or P53 mutations, simply because they divide 
more frequently than normal cells.
The Human DMP1 (hDMP1) Gene
Bodner et al. sequenced three independent EST 
(expressed sequence tag) clones for the hDMP1 
gene and reported that the human DMP1 protein 
consists of 760 amino acids. The DMP1 protein 
has very high structural homology with its murine 
counterpart (96% similarity at amino acid levels), 
and the sequence of the three myb-like repeats is 
completely identical. The hDMP1 gene is located 
on human chromosome 7q21, a locus often deleted 
in some human carcinomas and hematopoietic 
malignancies (Bieche et al. 1992; Bodner et al. 
1999; Kerr et al. 1996; Trovato et al. 2004). Inter-
estingly, the FISH analysis of leukemic samples 
with abnormalities on chromosome 7 showed that 
one allele of the hDMP1 gene was deleted in 9 of 
9 cases, suggesting the involvement of the DMP1 
locus in 7q- leukemias (Bodner et al. 1999).
Tschan et al. reported that the locus of hDMP1 
encodes at least three splicing variants (hDMP1α, 
β and γ) (Tschan et al. 2003). The hDMP1β and 
hDMP1γ isoforms have been cloned by RT-PCR, 
using the cDNA library of KG-1 cells. The open 
reading frames of hDMP1β and hDMP1γ encode 
identical initial amino acid (aa) sequences to 
hDMP1α up to the splice site at aa 237. However, 
after aa 237, hDMP1β and hDMP1γ show novel 
sequences of 35 and 48 aa, respectively, followed 
by a premature stop codon occurring in the alter-
natively spliced intronic sequence. The hDMP1β 
and γ isoforms still contain the acidic N-terminal 
transactivation, the cyclin D binding, and a part of 
the Myb-homology domains but no C-terminal 
transactivation domain. The predicted length of 
proteins encoded by hDMP1α, -β and -γ are 760, 
272, and 285 aa, respectively. The β- and γ-splicing 
variants do not bind to DNA, but they can inhibit 
transactivation of the CD13/Aminopeptidase N 
promoter by hDMP1α (Tschan et al. 2003). The 
full-length hDMP1α corresponds to murine Dmp1, 
which directly binds to the Arf promoter and 
positively regulates the p19
Arf-p53 pathway (Inoue 
et al. 1999). Therefore, it has been speculated that 
hDMP1α engages in tumor-suppressor activity. 
The hDMP1β and γ genes are speciﬁ  cally expressed 
in immature hematopoietic cells. Interestingly, 
U937 cells that constitutively express hDMP1β 
isoform showed reduced cell surface expression 
of CD13/Aminopeptidase N and continued to 
proliferate even after phorbol 12-myristate 
13-acetate treatment (Tschan et al. 2003). There-
fore, it was suggested that splicing abnormalities 
of hDMP1 that result in the overexpression of 
hDMP1βγ   isoforms may contribute to human 
leukemogenesis (Tschan et al. 2003).
Dmp1 and Lung Cancer: 
From Mouse Models 
to Human Disease
As mentioned earlier, the Dmp1 promoter receives 
oncogenic signaling from mutant Ras. The 
K-ras
LA/+ (K-ras
LA1/+, K-ras
LA2/+) mouse model is 
one of the most sophisticated models that mimics 
human non-small cell lung cancer (NSCLC) 
(Johnson et al. 2001; for comprehensive review of 
mouse models of lung cancer, see Meuwissen and 
Berns, 2005). In this model, the K-ras gene is 
controlled by its own promoter and is activated 
during spontaneous recombination events in the 
whole animal (Johnson et al. 2001). On the other 
hand, Dmp1-knockout mice are prone to tumor 
development, especially lung adenocarcinomas 
(Inoue et al. 2000, 2001). Based on this information, 217
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we crossed Dmp1-deﬁ  cient mice with K-ras
LA mice 
and reported that K-ras
LA-induced lung carcino-
genesis was significantly accelerated in both 
Dmp1
+/− and Dmp1
−/− mice, with little difference 
between the two cohorts (Mallakin et al. 2007). 
The lung tumor cells from Dmp1
+/−; K-ras
LA mice 
expressed Dmp1 mRNA 2–4 times higher than in 
lungs from Dmp1
+/− mice in most cases, suggesting 
endogenous Dmp1 promoter activation by onco-
genic K-Ras (Mallakin et al. 2007). Our report 
suggested the haploid-insufﬁ  ciency of Dmp1 in 
lung cancer suppression.
K-ras
LA lung tumors are different from Eµ-Myc 
lymphomas in that neither bi-allelic Arf deletion 
or Mdm2 overexpression were found in any 
tumors, regardless of the genotype of Dmp1 
(Eischen et al. 1999; Inoue et al. 2001; Mallakin 
et al. 2007). None of the Ink4a/Arf modulators, 
such as Bmi1, Twist, Tbx2/3, and Pokemon were 
overexpressed in K-ras
LA lung tumors, ruling out 
the possibility of the involvement of these Ink4a/
Arf modulators for K-ras-induced tumor formation. 
p53 mutation was less frequent in lung tumors from 
Dmp1
+/−, Dmp1
−/−; K-ras
LA mice, thus Dmp1 dele-
tions and p53 mutations might have similar effects. 
In fact, we have found that tumors that showed 
deletion of Dmp1 tended to show the phenotype 
of adenocarcinomas (5/7, 71%) (Mallakin et al. 
2007). All the lung tumors that showed mutation 
of p53 were adenocarcinomas (4/4, 100%). On the 
other hand, lung tumors that did not show Dmp1 
or p53 alterations were mostly adenomas, and there 
was only one case of adenocarcinoma in this group 
(1/5, 20%). Thus, deletions of Dmp1 or mutations 
of p53 are frequently associated with malignant 
phenotypes of K-ras
LA lung tumors.
In human lung cancers, p14
ARF is inactivated in 
65% of small-cell lung cancer (SCLC), while the 
gene is deleted in ∼20% of NSCLC. Promoter 
hypermethylation of ARF has been reported in 
∼10% of NSCLC, but is less frequent than that of 
p16
INK4a (∼40%) on the same locus (Meuwissen 
and Berns, 2005). We recently analyzed loss of 
heterozygosity (LOH) of hDMP1, INK4a/ARF, 
and P53 in more than 50 cases of human NSCLC 
samples (Mallakin et al. 2007). LOH of hDMP1 
was found in ∼35% (41% if we use relaxed criteria) 
of NSCLC (Fig. 4). Interestingly, the LOH of the 
hDMP1 locus and that of the INK4a/ARF or P53 
loci occurred in a mutually exclusive fashion, 
consistent with the hypothesis that hemizygous 
deletion of hDMP1 may inactivate the ARF-P53 
pathway (Mallakin et al. 2007; Fig. 4). The region 
that was deleted in human lung cancer was limited 
to the hDMP1 locus in ∼80% of the cases, indicat-
ing that lung cancer cells speciﬁ  cally target the 
hDMP1 gene (Mallakin et al. 2007). Point muta-
tions, promoter hypermethylations, and splicing 
alterations that result in hDMP1β overexpression 
were not common in human NSCLC. The hDMP1 
protein was very low or barely detectable in the 
nuclei of NSCLC cells that showed LOH of 
hDMP1 (Mallakin et al. 2007). Interestingly, 
expression and activation of Dmp1:ER in the ARF
+ 
P53 wild-type lung cancer cell line strongly inhib-
ited the growth of the cells, while other lung can-
cer cells with deletion of ARF or P53 were 
relatively resistant (Mallakin et al. 2007). Thus, it 
is highly possible that the hDMP1 gene is inacti-
vated in a signiﬁ  cant percentage of other types of 
human cancers, especially those that retain wild-
type ARF and P53. Hence, ‘reactivation’ of the 
hDMP1 gene in cancer cells might be a feasible 
INK4a/ARF P53
hDMP1
41%
36% 46%
13%
4%
5%
23%
(9%)
(32%)
(14%)
Figure 4. Deletion of hDMP1 is a new category of human lung 
cancer. 
Fifty-one cases of human non-small cell carcinoma (NSCLC) were 
studied for loss of heterozygosity (LOH) with 6 sets of PCR primers 
(2 sets for the hDMP1 locus, 2 sets for the INK4a/ARF locus, and 2 
sets for the P53 locus) (Mallakin et al. 2007). The numbers show the 
percentage of lung cancer samples that showed LOH for each tumor 
suppressor locus with our relaxed criteria, i.e. the LOH values showed 
2.0 or 0.5 with one of the two sets of primers. The numbers in 
parenthesis show the percentages of LOH cases that do not overlap 
LOH of other loci. Eighty-seven percent of NSCLC showed LOH with 
at least one of these sets of primers. LOH of hDMP1 occurred in a 
mutually exclusive fashion with LOH of INK4a/ARF or that of P53 in 
most cases. On the other hand, a signiﬁ  cant percentage of samples 
showed LOH for both INK4a/ARF and P53.218
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approach for novel cancer therapy since tumor cells 
often have one intact hDMP1 allele.
Conclusion and Future Directions
Dmp1 is a Myb-like transcription factor that is 
haplo-insufﬁ  cient for tumor suppression and is a 
physiological regulator of the Arf-p53 pathway. 
The Dmp1 promoter is activated by oncogenic 
Ras-Raf signaling, but is inhibited by physiologi-
cal mitogen, aberrant E2F expression, and geno-
toxic stimuli mediated by NF-κB. It will be helpful 
to conduct double staining of Dmp1 vs. c-Jun/
JunB, E2Fs, and NF-κB in tissues to understand 
their relationships during cell growth and differ-
entiation. In contrast to the accumulation of infor-
mation on the Dmp1 promoter, very little is known 
about the Dmp1 protein. Future studies will clarify 
the mechanism of post-translational modiﬁ  cations 
and identiﬁ  cation of novel binding and transcrip-
tional targets of Dmp1. Our recent study shows 
that the hDMP1 gene is deleted in a signiﬁ  cant 
percentage of human lung cancers, indicating its 
primary involvement in human carcinogenesis. 
Judging from the tumor spectra of Dmp1-knockout 
mice, it should be involved in a variety of malig-
nancies. Thus, it will be crucial to study inactiva-
tion/aberrant expression of hDMP1 in a broad 
spectrum of human cancers, and correlate the 
results with patients’ prognoses to apply the results 
of basic studies to clinical levels.
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